Rehabilitation company Reflexion Health Monday announced encouraging results from a randomised controlled clinical trial "Virtual Exercise Rehabilitation In-home Therapy: A Research Study (VERITAS)" conducted independently by the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine.
VERITAS is the first large-scale randomised controlled clinical trial that compares virtual physical therapy with traditional physical therapy. It was designed to evaluate the cost and clinical non-inferiority of using a virtual rehabilitation platform to deliver physical therapy following total knee replacement (TKR) surgery, said the company.
In the study, VERA, the company's US FDA-cleared Virtual Exercise Rehabilitation Assistant, enabled a substantial reduction in post-acute costs and rehospitalisations, while being as effective as traditional physical therapy.
The VERITAS was a multi-centre, randomised controlled trial that enrolled 306 adult participants scheduled for TKR surgery at four US sites. The treatment group concluded with 143 adults who received the company's VERA both pre- and post-surgery, compared with a control group of 144 adults who received traditional in-home or clinic-based physical therapy at participating sites.
Clinical outcomes, health service use and costs were examined for three months after surgery. The safety endpoints for patients with virtual physical therapy were similar over traditional in-home or clinic-based physical therapy, added the company.
Additionally, the company's VERITAS study results demonstrated an average cost savings of USD2,745 per patient for those who received virtual physical therapy using VERA technology over usual care with traditional physical therapy.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval